Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis

BMC Musculoskeletal Disorders

Nurullah Akkoc⁵  Necati Gunay³  Hulya Yalcin⁴  Ayfer Colak⁴  Servet Akar⁵  Didem Kozaci²  Safak Bilge⁶  Baris Akinci⁷  Ismail Sari⁵  Ali Taylan¹ 

[1] Izmir Tepecik Training and Research Hospital, Department of Rheumatology, Izmir, Turkey;Adnan Menderes University School of Medicine, Department of Biochemistry, Aydin, Turkey;Adnan Menderes University, Bilim ve Teknoloji Araştirma ve Uygulama Merkezi (ADU-BILTEM), Aydin, Turkey;Izmir Tepecik Training and Research Hospital, Department of Biochemistry, Izmir, Turkey;Dokuz Eylul University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey;Izmir Tepecik Training and Research Hospital, Department of Physical medicine and Rehabilitation, Izmir, Turkey;Izmir Tepecik Training and Research Hospital, Department of Endocrinology, Izmir, Turkey

关键词: DKK-1;    RANKL;    OPG;    Bone mineral density;    Ankylosing spondylitis;   

Others  :  1139083
DOI  :  10.1186/1471-2474-13-191

 received in 2012-02-17, accepted in 2012-09-26,  发布年份 2012

【 摘 要 】

Background

Ankylosing spondylitis (AS) is a chronic inflammatory disease of spine and sacroiliac joints; it is characterized by new bone formation, and the disease processes can be accompanied by osteoporosis. In the present study, we investigated changes in bone mineral density (BMD) and in the levels of various bone turnover-related biomarkers and cytokines in a cohort of AS patients, with regard to clinical parameters, disease activity, and treatment regimen.

Methods

55 AS patients and 33 healthy controls included in the study. Spinal mobility was assessed by the Bath Ankylosing Spondylitis Metrology Index (BASMI), and radiologic changes were scored by the Bath Ankylosing Spondylitis Radiologic Index (BASRI). Patients were also evaluated with the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Bone mineral density (BMD) assessed by dual energy X-ray absorptiometry. Various biomarkers and cytokines of bone turnover including osteoprotegerin (OPG), serum band 5 tartrate-resistant acid phosphatase (TRAP-5), soluble receptor activator of nuclear factor kappa-B ligand (sRANKL), secreted frizzled-related protein 1 (sFRP-1), Dickkopf-related protein 1 (DKK-1), and sclerostin were studied.

Results

The levels of TRAP-5, NTX, sRANKL, sclerostin, sFRP-1, DKK-1, and IFNγ, were similar between the patients and controls (p > 0.05), while BMD of femoral neck, and OPG levels were significantly lower in AS patients (p < 0.05). In a subgroup analysis, patients with active disease had significantly higher concentrations of OPG compared with the inactive group. Rest of the biomarkers and cytokines of bone turnover were similar between the active and inactive disease groups. Subgroup analysis of patients receiving anti-TNFα agents and conventional therapy revealed that OPG concentrations were significantly lower in the patients receiving biological drugs, while BAP and DKK-1 were significantly higher in the patients treated with conventional agents.

Conclusions

In this cross-sectional study we showed that OPG levels were significantly lower in AS patients compared to healthy subjects. On the other hand, the levels of wingless (Wnt) signal pathway inhibitors seem not altered. Ectopic bone formation in AS may be related to dysfunction of these molecules at the cellular level.

【 授权许可】

   
2012 Taylan et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Schett G: Bone formation versus bone resorption in ankylosing spondylitis. Adv Exp Med Biol 2009, 649:114-121.
• [2]Carter S, Lories RJ: Osteoporosis: a paradox in ankylosing spondylitis. Curr Osteoporos Rep 2011, 9:112-115.
• [3]Magrey M, Khan MA: Osteoporosis in ankylosing spondylitis. Curr Rheumatol Rep 2010, 12:332-336.
• [4]Schett G: Joint remodelling in inflammatory disease. Ann Rheum Dis 2007, 66(Suppl 3):iii42-iii44.
• [5]Schett G, Zwerina J, David JP: The role of Wnt proteins in arthritis. Nat Clin Pract Rheumatol 2008, 4:473-480.
• [6]Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT: Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol 2010, 29:1155-1161.
• [7]Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonpoulos AP: Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010, 62:150-158.
• [8]Franck H, Meurer T, Hofbauer LC: Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004, 31:2236-2241.
• [9]Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, Spitzauer S, Grampp S, Kainberger F, Ebner W, Smolen JS, Pietschmann P: Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002, 29:1430-1436.
• [10]Im CH, Kang EH, Ki JY, Shin DW, Choi HJ, Chang EJ, Lee EY, Lee YJ, Lee EB, Kim HH, Song YW: Receptor activator of nuclear factor kappa B ligand-mediated osteoclastogenesis is elevated in ankylosing spondylitis. Clin Exp Rheumatol 2009, 27:620-625.
• [11]Kim HR, Lee SH, Kim HY: Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology 2006, 45:1197-1200.
• [12]Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, Kim HA, Choi HJ, Park W: Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int 2012, 32(8):2523-2527.
• [13]Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards W, Kronke G, Schett G: Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 2010, 69:592-597.
• [14]Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG: Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther 2011, 13(Suppl 1):S4.
• [15]Schett G: Structural bone changes in spondyloarthritis: mechanisms, clinical impact and therapeutic considerations. Am J Med Sci 2011, 341(4):269-271.
• [16]van der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. a proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
• [17]Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A: Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994, 21:1694-1698.
• [18]MacKay K, Mack C, Brophy S, Calin A: The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 1998, 41:2263-2270.
• [19]Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallori P, Jenkinson T: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-2285.
• [20]Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-2291.
• [21]Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352.
• [22]Take I, Kobayashi Y, Yamamoto Y, Tsuboi H, Ochi T, Uematsu S, Okafuji N, Kurihara S, Udagawa N, Takahashi N: Prostaglandin E2 strongly inhibits human osteoclast formation. Endocrinology 2005, 146:5204-5214.
• [23]Walsh NC, Gravallese EM: Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 2010, 233:301-312.
• [24]Woo JH, Lee HJ, Sung IH, Kim TH: Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007, 34:1753-1759.
• [25]Schett G: Osteoimmunology in rheumatic diseases. Arthritis Res Ther 2009, 11:210. BioMed Central Full Text
• [26]Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G: Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163.
• [27]Lane EN, Nevitt MC, Lui LY, de Leon P, Corr M: Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women. Arthritis Rheum 2007, 56:3319-3325.